
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Brian Kelley is vice president, bioprocess development at Genentech, Inc.
Altering the order of operations, using new resins, and increasing dynamic binding capacity can obviate the need for major facilty changes.
Published: March 2nd 2009 | Updated: